REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
8.70
+0.02 (0.23%)
At close: Jul 14, 2025, 4:00 PM
8.70
0.00 (0.00%)
After-hours: Jul 14, 2025, 4:00 PM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $89.01M in the quarter ending March 31, 2025, with 469.79% growth. This brings the company's revenue in the last twelve months to $156.72M, up 80.70% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.
Revenue (ttm)
$156.72M
Revenue Growth
+80.70%
P/S Ratio
2.82
Revenue / Employee
$443,960
Employees
353
Market Cap
438.38M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
RGNX News
- 4 days ago - REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy - PRNewsWire
- 5 weeks ago - Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
- 5 weeks ago - Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer - Benzinga
- 5 weeks ago - REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PRNewsWire
- 6 weeks ago - REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 2 months ago - REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - PRNewsWire
- 2 months ago - FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - PRNewsWire
- 2 months ago - REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript - Seeking Alpha